Navigation Links
3SBio Inc. Schedules Unaudited Fourth Quarter and Full Year 2012 Results
Date:3/3/2013

SHENYANG, China, March 3, 2013 /PRNewswire/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it will release its unaudited fourth quarter and full year 2012 results on Tuesday, March 19, 2013 at 8:00am China Standard Time.

Following the earnings announcement, 3SBio's senior management will host a conference call on Tuesday, March 19, 2013 8:00pm China Standard Time (8:00am US Eastern or 5:00am US Pacific) to discuss its unaudited fourth quarter and full year 2012 results and recent business activity. The conference call may be accessed using the dial-in numbers below:

Conference ID: 15890708

Local dial-in:
China landline: 800-819-0121
China mobile: 400-620-8038
Hong Kong : 852-2475-0994
United States: 718-354-1231

International toll-free dial-in:
Hong Kong: 800930346
United States: 1-866-519-4004
United Kingdom: 080-8234-6646

International toll dial-in: 65 6723 9381

Replay- Conference ID: 15890708
A telephone replay will be available two hours after the call until March 27, 2013 at:
International: 61-2-8235-5000
United States: 1-866-214-5335

Webcast
A live webcast of the conference will be available on the investor relations section of 3SBio's website at www.3sbio.com and at http://www.media-server.com/m/p/bcshv7v5.

A replay of the webcast will be available within one hour after the conclusion of the call.'/>"/>

SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
2. 3SBio Independent Committee Selects Legal Counsel in connection with Going Private Proposal
3. 3SBio Inc. Announces Receipt of "Going Private" Proposal at $15 Per ADS
4. 3SBio Inc. to Hold 2012 Annual General Meeting on October 10, 2012
5. Apexigen Announces the Filing of an IND by its Partner, 3SBio
6. 3SBio Inc. Announces Changes to Its Board of Directors
7. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
8. 3SBio Obtains SFDA Approval to Join Global Phase III Trial for Voclosporin
9. 3SBio Inc. To Present at the DB Access Asia Conference 2012
10. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
11. GSI Group Inc. Schedules Earnings Release and Conference Call for Tuesday, March 12, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 According to a ... Catheter (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), ... (AF, VT, WPW) - Global Forecasts to 2019 ", published ... reach around ~$4.73 Billion by 2019 with a CAGR ... 2019. Browse   90   ma ...
(Date:3/27/2015)... 2015 The International Myeloma Foundation (IMF) – ... working toward prevention and a cure – today commended ... federal resolution (H. Res. 174) that supports the designation ... Myeloma Awareness Month." Currently there are more ... than 110,000 new cases are diagnosed yearly, according to ...
(Date:3/27/2015)... 27, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... today announced that they have entered into ... and proprietary sd-rxRNA® technology for use in ... has the potential to result in novel, ... that could be a significant step toward ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
... pirfenidone may provide meaningful clinical benefit in IPF patients ... reported -- Conference Call and Webcast at 9 p.m. ... InterMune, Inc. (Nasdaq: ITMN ) reported ... evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) ...
... 19 New data demonstrate that maintenance therapy with ... time to relapse compared to placebo in patients with ... this week at a major medical meeting. Bipolar ... in a person,s mood, energy and ability to function. ...
Cached Medicine Technology:Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 2Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 3Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 4Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 5Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 6Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 7Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 8Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 9Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 10Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 11Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS) 12RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 2RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 3RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 4RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 5RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 6RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 7RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 8RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 9RISPERDAL(R) CONSTA(R) (Risperidone) Long-Acting Treatment Delayed the Time to Relapse in Patients with Bipolar I Disorder 10
(Date:3/27/2015)... Alberta (PRWEB) March 27, 2015 In her ... then, prevented her from working, Monica K. arrived at ... the mending department quiet, defensive and scared. The owners and ... & Support Services (EPSS) to offer jobs to challenged ... take patience and a willingness to begin with the end ...
(Date:3/27/2015)... March 27, 2015 First Choice Emergency ... The new facility is located 12665 W Lake Houston Pkwy, ... resident of Summerwood, I look forward to delivering the highest ... Sowell, Facility Medical Director of First Choice Emergency Room Summerwood. ... Room made a donation to Summer Creek High School at ...
(Date:3/27/2015)... Healthpointe is proud to announce that ... now treating knee and hip joint disorders in practice ... Beach, and La Mirada. Dr. Stanley Katz specializes in ... joint disorders as well as chronic conditions such as ... his patients back to their normal lives. Many ...
(Date:3/27/2015)... 2015 The report “CountryFocus Healthcare, ... essential source of information on and analysis of ... Germany’s increasingly elderly population and its associated disease ... In 2013, the elderly accounted for 27.1% of ... Annual Growth Rate (CAGR) of 1.2% to 29.5% ...
(Date:3/27/2015)... According to a recently published report series ... screw market in Europe is in decline due to ... segment. Price decreases are being seen across the entire ... the total European trauma device market, continued pricing pressure ... year after year. , “Such price drops are ...
Breaking Medicine News(10 mins):Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:First Choice Emergency Room Opens New Facility in Houston, Texas 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 2Health News:Fellowship-Trained and Board-Certified Orthopedic Surgeon is Now Treating Knee and Hip Joint Disorders in Anaheim, California 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 2Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 3Health News:Germany Healthcare, Regulatory and Reimbursement Landscape Market Research Report Available at RnRMarketResearch.com 4Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3
... geneticist at the University of Edinburgh, Scotland, had announced on ... called Uqcrc1 in the brains of mouse used as models ... powerhouses of the cells to work overtime. Dr. Bird stated ... been linked to Rett Syndrome. The co-author of the study ...
... that the male survivors of childhood sexual abuse ... understood// many health care practitioners as well as ... male and female childhood sexual survivors usually exhibit ... encounters with health care professionals, there are gender ...
... Mental health experts have said that New Orleans seems ... post-traumatic stress// disorder of an intensity rarely seen in ... that existed before hurricane Katrina struck, 10 months ago. ... has almost collapsed completely leaving the police department to ...
... Celiac Sprue Research Foundation have claimed to discover a ... is an inherited inflammatory disorder of the small intestine ... The two research studies that have been published in ... the way for clinical testing with an oral enzyme ...
... recalled almost around 20,000 chocolate bars in Britain as ... bars may contain traces of salmonella. ,A ... minute traces of salmonella, which though quite are significantly ... for any hazards. The spokesperson had also clarified that ...
... announced their plans to use a protein that has been ... ice creams using genetically// modified technology. ,The parent ... them to develop ice creams that are of low-calorie, and ... technology to make newer versions of their best selling products ...
Cached Medicine News:Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 2Health News:Researchers Have Linked Rett Syndrome to Mitochondrial Gene 3Health News:Sexually Abused Males Found Struggling In heir relations with Healthcare Providers 2Health News:Scientists Discover Non-dietary Therapy For Celiac Diseases 2Health News:Wall's To Develop Low-fat Ice-cream Using Fish Blood 2
The Mini Anchor is an exceptionally strong, versatile anchor. This anchor comes in either a load-your-own or QUICKANCHOR format, preloaded on either 2/0 or 0 ETHIBOND EXCEL suture with swaged needles...
... titanium alloy implants used for ... They are indicated where high ... SuperAnchor uses four Nitinol arcs ... small size. The unique design ...
The 4mm diameter Revo suture anchor is designed primarily for arthroscopic and open rotator cuff repair. Additional applications include other shoulder repair procedures, as well as use in knees and ...
The Linvatec UltraFix Suture Anchor System's smooth surface until deployed eliminates tissue, bone and suture damage and its ultra smooth eyelet hole preserves suture integrity....
Medicine Products: